A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. (September 2017)

• Record Type: Journal Article
• Authors: Fujimoto, Daichi; Morimoto, Takeshi; Ito, Jiro; Sato, Yuki; Ito, Munehiro; Teraoka, Shunsuke; Otsuka, Kojiro; Nagata, Kazuma; Nakagawa, Atsushi; Tomii, Keisuke
• Is Part Of: Lung cancer. Volume 111(2017)
• Page Start: 1
• Page End: 5
• Publication Date: 2017-09
• Subjects: NSCLC non-small cell lung cancer -- irAE immune-related adverse events -- IIP idiopathic interstitial pneumonia -- UIP usual interstitial pneumonia -- PD-1 programmed cell death 1 -- ILD interstitial lung disease -- AE-IIP acute exacerbation of idiopathic interstitial pneumonia -- ECOG Eastern Cooperative Oncology Group -- PS performance status -- %VC vital capacity (as percent of predicted); Nivolumab -- Non-small cell lung cancer -- Interstitial pneumonia -- Interstitial lung disease; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2017.06.008
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Nivolumab therapy is challenging in NSCLC patients with IIP. We performed the pilot study to evaluate the safety of nivolumab in these patients. None of the patients had severe adverse events. Response was observed in 3 patients (50%). Nivolumab therapy was feasible in NSCLC patients with mild IIPs. Abstract: Introduction: Nivolumab has demonstrated efficacy against metastatic non-small cell lung cancer (NSCLC). However, immune-related adverse events can occur, among which pneumonitis is relatively common. Lung cancer patients with idiopathic interstitial pneumonia (IIP) have a higher risk of pneumonitis associated with anticancer therapy. We hypothesized that the benefit of nivolumab may outweigh the risks of pneumonitis in patients with NSCLC who have mild IIP. We performed a pilot trial to evaluate the safety of nivolumab in NSCLC patients with mild IIP. Methods: Previously treated, inoperable NSCLC patients with mild IIP were enrolled. Mild IIP was defined as having a predicted vital capacity ≥80% and a possible usual interstitial pneumonia (UIP) or inconsistent with UIP pattern on chest high-resolution computed tomography. Patients received nivolumab at a dose of 3 mg/kg biweekly. Results: Six patients were enrolled in this trial between April 2016 and December 2016. None experienced drug-related nonhematologic grade 3/4 or hematologic grade 4 adverse events in the 12 weeks following the initiation of nivolumab treatment. Furthermore, none of the patients had pneumonitis of any grade. At the time of analysis, all patients were alive, and 3 had experienced a partial response. Conclusions: Nivolumab therapy may be feasible in NSCLC patients with mild IIP. (Trial registration number: UMIN000022037)